Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEER-3: RGN-259 for Neurotrophic Keratopathy
2022-502697-16-00Phase 3Completed
- Sponsor
- ReGenTree
- Start
- Jun 2023
- Modality
- Peptides
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in neurotrophic keratitis (NK) comparing RGN-259 0.1% ophthalmic solution with Placebo ophthalmic solution (2 arms). Primary endpoints: Complete healing of persistent epithelial defect at Day 29 (Central Reading Center) and Safety. Started Jun 2023; status: completed.
02
Drugs
timbetasin
03
Conditions
neurotrophic keratitis (NK)
Beyond the preview
Go deeper on 2022-502697-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502697-16-00.